1_phenomeneMassif
π Health and biotech
How science is preparing for antibiotic resistance

The multiple forms of antibiotic resistance

with Agnès Vernet, Science journalist
On March 16th, 2022 |
3min reading time
Philippe Glaser
Philippe Glaser
Research Director in Ecology at Institut Pasteur
Key takeaways
  • Antibiotic resistance occurs when a bacterium survives a dose of antibiotics that would normally kill it.
  • There is a reservoir of genes responsible for antibiotic resistance and a wide variety of biological mechanisms.
  • Antibiotic treatments will select for resistant bacteria and promote the transfer of this ability from one bacterium to another.
  • A better understanding of the mechanisms involved in resistance is essential for developing more effective antibiotics or combinations of treatments.

Anti­bio­tic resis­tance is a com­plex pro­blem. It occurs when a bac­te­rium sur­vives a dose of anti­bio­tics that would nor­mal­ly kill it. This concept is thus direct­ly lin­ked to the way in which the anti­bio­tic mole­cule acts on the micro-orga­nism and the­re­fore to how the micro-orga­nisms can pro­tect them­selves. There is a wide varie­ty of bac­te­ria that are poten­tial­ly patho­ge­nic to humans and ani­mals, and many dif­ferent anti­bio­tic mole­cules. Unders­tan­ding their inter­ac­tions, both at the level of a cell and at the level of a popu­la­tion of cells, is essen­tial for unders­tan­ding anti­bio­tic resistance.

Molecular shields

There are two types of resis­tance : intrin­sic and acqui­red. The first applies, for example, to bac­te­ria whose very struc­ture forms a pro­tec­tive layer against a toxic mole­cule. Take, for example, van­co­my­cin, an anti­bio­tic that is effec­tive against Sta­phy­lo­coc­cus aureus or ente­ro­coc­ci, which are gram-posi­tive bac­te­ria. But for Esche­ri­chia coli or Pseu­do­mo­nas aeru­gi­no­sa, which are gram-nega­tive, this anti­bio­tic does not reach its tar­get. These bac­te­ria are so-cal­led because they have a double mem­brane that pre­vents the pene­tra­tion of the stain deve­lo­ped by the Danish bac­te­rio­lo­gist Hans Chris­tian Gram and thus cer­tain anti­bio­tics. The tar­get of van­co­my­cin is indeed loca­ted bet­ween these two mem­branes. Other mole­cules capable of cros­sing the outer­most mem­brane, such as anti­bio­tics of the peni­cil­lin fami­ly, must the­re­fore be used against these types of bacteria.

It is acqui­red anti­bio­tic resis­tance that explains the cri­sis we are cur­rent­ly expe­rien­cing. It concerns micro-orga­nisms that were pre­vious­ly sen­si­tive to a mole­cule to treat an infec­tion and no lon­ger are. Bac­te­ria have two ways of lear­ning to pro­tect them­selves from a toxic mole­cule. As they divide, they can accu­mu­late muta­tions which, by alte­ring the tar­get of the anti­bio­tic or pre­ven­ting it from ente­ring the cell, ren­der it ineffective.

The second way of acqui­ring resis­tance relies on mobile gene­tic ele­ments, i.e. pieces of DNA that can move from one cell to ano­ther. These are usual­ly plas­mids, cir­cu­lar, auxi­lia­ry mini-chro­mo­somes that bac­te­ria exchange, even bet­ween dif­ferent spe­cies. These plas­mids are for­mi­dable from the point of view of anti­bio­tic resis­tance because they can car­ry seve­ral genes for resis­tance to dif­ferent classes of anti­bio­tics. A bac­te­rium can thus become mul­ti-resis­tant by the simple acqui­si­tion of such a plasmid.

Bacterial ecology

Plas­mids, and the resis­tance genes they car­ry, are also res­pon­sible for much of the anti­bio­tic resis­tance of the com­men­sal bac­te­ria of our diges­tive sys­tem. These bac­te­ria can receive plas­mids contai­ning resis­tance genes from bac­te­ria in their envi­ron­ment that are less well adap­ted to the gut eco­sys­tem. Resis­tance will thus spread among the micro­bio­ta, consti­tu­ting a “silent reserve” with cli­ni­cal conse­quences that have yet to be evaluated.

The action of an anti­bio­tic depends on the living condi­tions of a bac­te­rium, which some­times com­pli­cates the inter­pre­ta­tion of labo­ra­to­ry diag­noses. A bac­te­rium may be sen­si­tive to an anti­bio­tic in a petri dish, but resis­tant in the patient, or vice ver­sa. The action of the treat­ment and the res­ponse of the bac­te­ria vary accor­ding to the envi­ron­ment ; they will not be iden­ti­cal in blood, urine or labo­ra­to­ry condi­tions. Fur­ther­more, the anti­bio­tic alone can rare­ly eli­mi­nate an infec­tion-cau­sing bac­te­rium because it works with the patient’s immune res­ponse. Work, such as our Seq2Diag pro­ject, aims to inte­grate these para­me­ters to improve diagnosis.

The stu­dy of resis­tance also includes the popu­la­tion dyna­mics of bac­te­ria. During an infec­tion, a large num­ber of bac­te­rial cells in dif­ferent envi­ron­ments are invol­ved and not all are iden­ti­cal. Those that are able to sur­vive the admi­nis­te­red dose of an antio­bio­tic will take advan­tage of the space freed by the sus­cep­tible ones to multiply.

This struggle for space is at the very ori­gin of some anti­bio­tics and resis­tance genes. Many anti­bio­tics, such as strep­to­my­cin, used to treat tuber­cu­lo­sis, have them­selves been iso­la­ted from bac­te­ria. Bac­te­ria pro­duce these mole­cules to pro­tect their own space and to take over space from the sen­si­tive bac­te­ria with which they coha­bit. Logi­cal­ly, a bac­te­rium that syn­the­sises an anti­bio­tic is, in one way or ano­ther, resis­tant to that mole­cule. Anti­bio­tics and resis­tance are natu­ral phe­no­me­na in the dyna­mics of many bacteria.

Predicting resistance

One of the main ques­tions facing scien­tists today concerns the appea­rance of resis­tance. Can it be pre­dic­ted ? The pro­blem is com­plex and relies lar­ge­ly on moni­to­ring cir­cu­la­ting strains and ana­ly­sing their genomes. 

This involves com­pi­ling the genome sequences of bac­te­ria consi­de­red to have an aty­pi­cal resis­tance pro­file. When the resis­tance mecha­nism is not reco­gni­sed in the genome, bio­lo­gists will try to elu­ci­date the pro­cess invol­ved and recons­truct its evo­lu­tio­na­ry his­to­ry. This infor­ma­tion could theo­re­ti­cal­ly help pre­dict the emer­gence of new resis­tance. Howe­ver, new mecha­nisms are rare and are now being detec­ted more qui­ck­ly. WHO’s GLASS net­work moni­tors anti­bio­tic-resis­tant bac­te­ria in low-income coun­tries. As part of the Prio­ri­ty Research Plan, the Com­mis­sa­riat aux inves­tis­se­ments d’a­ve­nir is fun­ding the deve­lop­ment of a data­base of bac­te­rial genomes lin­ked to anti­bio­tic resis­tance. This tool, cal­led ABRo­mics, will bring toge­ther, in a single struc­ture, all the frequent and rare resis­tances iden­ti­fied in France and will allow to moni­tor their pro­gress in real time. Such natio­nal data­bases are deployed in various coun­tries. They help to pre­dict the spread of strains that are dif­fi­cult to treat.

Support accurate information rooted in the scientific method.

Donate